Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Updated safety and efficacy results from RADIANT-2.
James Yao
Consultant or Advisory Role - Endo Pharmaceuticals; Ipsen; Novartis; Pfizer
Honoraria - Novartis
Research Funding - Genentech; Novartis
Sergio Ricci
No relevant relationships to disclose
Robert Winkler
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Valentine Jehl
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Marianne Pavel
Consultant or Advisory Role - Ipsen; Novartis; Pfizer
Honoraria - Ipsen; Novartis; Pfizer